Fig. 6

Clinical and in vitro validation of MITF in basal breast cancer. a Kaplan–Meier plot for basal breast cancer patients stratified by MITF staining score. Patient samples (n = 45) were divided into two groups based on MITF positivity (n = 10) and negativity (n = 35) in nuclei or cytoplasm staining. A significant difference in survival was observed between the groups (log-rank test, P = 0.006). The median survival was 1208 days for the positive staining group and 2406 days for the negative staining group. Source data are provided as a Source Data file. b Representative image of IHC staining with MITF antibody on a primary basal breast cancer tumor. c Volcano plot depicting the changes in representation (log₂-fold change, x-axis) and significance (−log10 adjusted P, y-axis) of shRNA expressing MDA-MB-436 cells targeting Mitf vs. Ren at day 17. qPCR-validated genes (Supplementary Fig. 10) labeled. Source data are provided as a Source Data file. d Hallmarks of cancer and REACTOME gene sets analyzed from the transcriptome analysis comparing MDA-MB-436 cells transduced with two independent MITF shRNAs and control. Enrichment score (ES) is shown. e Heat map based on the subset of differentially expressed genes where gene expression correlated with PSIONIC-inferred MITF activity across breast cancer cell lines (target genes with |ρ| > 0.4 shown). Expression values were transformed (VST) and corrected. The color coding in each cell reflects the deviation from the gene’s average across all samples. Red labels indicate positive correlation with inferred MITF activity, blue labels indicate negative correlation with inferred MITF activity. Bold labels indicate the existence of correlation in TCGA BASAL-BRCA tumors